FDA approves Sanofi/Regeneron colon cancer drug
date:Aug 06, 2012
ths for those receiving only FOLFIRI. Also, patients receiving Zaltrap went an average 6.9 months before their symptoms got worse, compared with 4.7 months for those on chemotherapy alone.
Zaltrap, like Avastin but through a different approach, blocks a protein called VEGF that tumors employ to create blood vessels that provide the nutrients. Erbitux blocks receptors to a different protein, called epidermal growth factor.
This is a very solid new opportunity for Regeneron, said RW Baird analyst
2/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/10 05:14